Skip to main content
Signal8
Launch Terminal

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc.

NASDAQ:SLSHealthcare
-4.68%$9.68
AH$9.67-0.11%vs close
Mkt Cap$1.95B
Float199.3M
O/S201.95M
Vol
$ Vol
RVOL
Inst Own36.5%
SI27.0%
Earnings
Dilution
SELLAS Life Sciences Group, Inc. logoNASDAQ:SLS$9.68-4.68%
Upcoming Catalysts
Phase Distribution
17 lead-sponsored trials·2 active·11 completed
Phase 12
Phase 1/24
Phase 27
Phase 32
Not applicable2
(2 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

    NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection

    Breast Cancer With Low to Intermediate HER2 Expression

    Enrollment
    758
    Start
    Nov 2011
    Primary Completion
    Sep 2016
    Completion
    Sep 2016
    NCT01479244
  • Phase 3
    Active, not recruiting

    Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

    Galinpepimut-S, Azacitidine

    Acute Myeloid Leukemia

    Enrollment
    127
    Start
    Feb 2021
    Primary Completion
    Dec 2025est.READOUT
    Completion
    Dec 2026est.
    NCT04229979
  • Phase 2
    Completed

    Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

    Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF

    Malignant Pleural Mesothelioma

    Enrollment
    41
    Start
    Dec 2010
    Primary Completion
    Nov 2016
    Completion
    Jul 2017
    NCT01265433
  • Phase 2
    Completed

    WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

    Galinpepimut-S, GM-CSF

    Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia

    Enrollment
    22
    Start
    Jan 2011
    Primary Completion
    Sep 2016
    Completion
    Sep 2016
    NCT01266083
  • Phase 2
    Completed

    A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

    RXI-109, Placebo

    Hypertrophic Scar

    Enrollment
    25
    Start
    Nov 2013
    Primary Completion
    Jun 2016
    Completion
    Jun 2016
    NCT02030275
  • Phase 2
    Completed

    A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

    RXI-109, Placebo

    Keloid

    Enrollment
    16
    Start
    Mar 2014
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT02079168
  • Phase 2
    Completed

    A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

    Anagrelide CR

    Thrombocytosis, Myeloproliferative Neoplasms

    Enrollment
    18
    Start
    May 2014
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT02125318
  • Phase 2
    Unknown status

    A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

    RXI-109

    Hypertrophic Scar

    Enrollment
    40
    Start
    Jul 2014
    Primary Completion
    Dec 2017
    Completion
    Mar 2018est.
    NCT02246465
  • Phase 2
    Unknown status

    Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

    Sensitizing DPCP Ointment, Treatment DPCP Ointment

    Common Warts, HPV (Human Papillomavirus) +2

    Enrollment
    83
    Start
    Dec 2015
    Primary Completion
    Jan 2018
    Completion
    May 2018est.
    NCT02640820
  • Phase 1/2
    Completed

    WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

    Galinpepimut-S, GM-CSF

    Multiple Myeloma

    Enrollment
    20
    Start
    Apr 2013
    Primary Completion
    Dec 2016
    Completion
    Nov 2017
    NCT01827137
  • Phase 1/2
    Unknown status

    Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

    RXI-109

    Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization +2

    Enrollment
    9
    Start
    Nov 2015
    Primary Completion
    Apr 2018est.
    Completion
    May 2018est.
    NCT02599064
  • Phase 1/2
    Completed

    Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

    galinpepimut-S, pembrolizumab

    Acute Myelogenous Leukemia, Ovarian Cancer +3

    Enrollment
    26
    Start
    Sep 2019
    Primary Completion
    Jul 2022
    Completion
    Oct 2022
    NCT03761914
  • Phase 1/2
    Recruiting

    Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

    SLS009, venetoclax

    Hematologic Malignancies

    Enrollment
    160
    Start
    May 2021
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT04588922
  • Phase 1
    Completed

    Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

    RXI-109, Placebo

    Cicatrix, Scar Prevention

    Enrollment
    15
    Start
    Jun 2012
    Primary Completion
    Apr 2014
    Completion
    May 2014
    NCT01640912
  • Phase 1
    Completed

    Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109

    RXI-109, Placebo

    Cicatrix, Scar Prevention

    Enrollment
    15
    Start
    Dec 2012
    Primary Completion
    Jun 2014
    Completion
    Nov 2014
    NCT01780077
  • Observational
    Completed

    Observational Registry Study of Quality of Life When Treating BTcP With Abstral

    Fentanyl

    Quality of Life, Breakthrough Cancer Pain

    Enrollment
    164
    Start
    Oct 2013
    Primary Completion
    Jun 2015
    Completion
    Jun 2015
    NCT01936636
  • Expanded access
    Available

    Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

    Galinpepimut-S

    Acute Myeloid Leukemia, Myelodysplastic Syndromes

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT05593185
Search ClinicalTrials.gov for “SELLAS Life Sciences Group”